Alkermes shares are rallying as the market continues to price in a bigger near-term revenue base following the close of its Avadel acquisition, which brought in the FDA-approved narcolepsy therapy LUMRYZ and established a foothold in sleep medicine. The combination has helped shift the investor focus from a legacy neuroscience portfolio to a more diversified commercial story with a newly consolidated growth asset and clearer 2026 revenue expectations tied to LUMRYZ.

For 2026, Alkermes has framed LUMRYZ as a meaningful contributor in its first year under Alkermes ownership, with expected net sales of $315 million to $335 million for the period from Feb. 12 through Dec. 31, 2026. Investors are also weighing acquisition-related accounting impacts, including an approximately $180 million LUMRYZ inventory fair value step-up that is expected to flow through cost of goods sold as the inventory is sold during 2026, which can cloud headline gross margin even as revenue rises.

With the deal now closed, the next debate for the stock is execution: whether Alkermes can expand LUMRYZ’s prescriber reach and maintain payer access while integrating Avadel’s operations and commercial team. Traders will also look for any incremental updates on the narcolepsy pipeline strategy and timelines as Alkermes positions itself as a broader sleep-medicine player rather than a single-product story.